What is the 13F Pro Quality Score for QDEL?

13F Pro ranks QuidelOrtho Corp (QDEL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View QDEL's current score at https://13fpro.ai/research/QDEL (free sign-up required for the full ranking).

Which hedge funds own the most QDEL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of QDEL include BlackRock,, FMR, Newtyn Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/QDEL as soon as new 13F filings post.

Where does 13F Pro source QDEL data?

All QuidelOrtho Corp fundamentals and ownership data come directly from SEC EDGAR. QuidelOrtho Corp files with the SEC under CIK 1906324. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is QDEL in?

QuidelOrtho Corp (QDEL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is QDEL research updated on 13F Pro?

QDEL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

QuidelOrtho Corp(QDEL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1906324 QDEL stock profile & AI dashboard →

13F Pro Quality Score

26.4/100

Rank #2,505 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

17.0/100

Profitability

12.4/100

Balance Sheet

12.1/100

Earnings Quality

30.0/100

Free Cash Flow

19.6/100

Institutional Flow

39.0/100

Revenue Scale

67.0/100

Dilution Risk

44.4/100

QDEL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for QuidelOrtho Corp (QDEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QDEL at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,505 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (12.1) and profitability (12.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 44.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), QuidelOrtho Corp reports quarterly revenue of $619.8M, net income of $-91.8M, free cash flow of $-67.0M. Top institutional holders of QDEL by reported 13-F value include BlackRock,, FMR, Newtyn Management,, based on the most recent SEC filings. QDEL trades on the Nasdaq exchange and files with the SEC under CIK 1906324. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QDEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QuidelOrtho Corp directly from SEC EDGAR. QuidelOrtho Corp's 13F Pro composite quality score has ranged between 8 and 71 since 2023, currently 26.4 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about QuidelOrtho Corp

Quirks, history, and lore behind QDEL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in San Diego, California · operates in the in vitro diagnostics space.
2
The Numbers
Annual revenue in the range of roughly $3 billion, built largely on the back of a pandemic-era testing boom that has since cooled considerably — the hangover is real.
3
The History
The company is itself the product of a major merger in 2022, combining two established diagnostics firms into a single mid-cap powerhouse with a combined history stretching back several decades.
4
The Secret
One half of its lineage built its name on rapid point-of-care tests for flu and strep; the other half was a global leader in transfusion medicine and clinical chemistry.
5
The Lore
Its COVID-19 rapid antigen tests flew off shelves and into medicine cabinets worldwide — then demand cratered, leaving the company scrambling to rebalance its portfolio post-pandemic.
6
The Giveaway
When Quidel swallowed Ortho Clinical Diagnostics in 2022, it mashed their names together into a ticker that reads like a game of corporate Scrabble: QDEL.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$619.8M

Net Income

Q1 2026

$-91.8M

Free Cash Flow

Q1 2026

$-67.0M

D/E Ratio

Q1 2026

1.58

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.9% YoY

$2.73BFY 2025

FY20 $1.66BFY23 $3.00BFY24 $2.78BFY25 $2.73B

Net Income

+44.8% YoY

$-1.13BFY 2025

FY20 $810.3MFY23 $-10.1MFY24 $-2.05BFY25 $-1.13B

Operating Income

+53.1% YoY

$-919.2MFY 2025

FY20 $1.06BFY23 $139.1MFY24 $-1.96BFY25 $-919.2M

EPS (Diluted)

+45.4% YoY

$-16.69FY 2025

FY20 $18.60FY23 $-0.15FY24 $-30.54FY25 $-16.69

Total Assets

-10.2% YoY

$5.77BFY 2025

FY20 —FY23 $8.56BFY24 $6.42BFY25 $5.77B

Total Debt

-3.7% YoY

$3.05BFY 2025

FY20 —FY23 $2.70BFY24 $3.17BFY25 $3.05B

Op. Cash Flow

+26.7% YoY

$105.2MFY 2025

FY20 $629.7MFY23 $280.2MFY24 $83.0MFY25 $105.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019
Revenue	$2.73B -1.9%	$2.78B -7.2%	$3.00B +80.4%	$1.66B	—
Net Income	$-1.13B +44.8%	$-2.05B -20216.8%	$-10.1M -101.2%	$810.3M	—
Operating Income	$-919.2M +53.1%	$-1.96B -1509.7%	$139.1M -86.9%	$1.06B	—
EPS (Diluted)	$-16.69 +45.4%	$-30.54 -20260.0%	$-0.15 -100.8%	$18.60	—
Total Assets	$5.77B -10.2%	$6.42B -25.0%	$8.56B	—	—
Total Debt	$3.05B -3.7%	$3.17B +17.4%	$2.70B	—	—
Operating Cash Flow	$105.2M +26.7%	$83.0M -70.4%	$280.2M -55.5%	$629.7M	—

AI Insight: QDEL Financial Trends

Equity has collapsed 42% over six quarters as persistent net losses and a massive Q3 2025 charge erode QDEL's balance sheet while debt remains stubbornly above $2.8B.

• Equity deteriorated from $3,187M in Q3 2024 to $1,851M in Q1 2026, a $1,336M decline driven by unrelenting net losses.

• Operating income has been negative in five of eight quarters; Q3 2025 operating loss of $705M dwarfs all prior periods.

• Revenue in Q1 2026 of $620M is below year-ago Q1 levels and shows no growth trajectory over the eight-quarter span.

• Operating cash flow turned positive in Q4 2025 at $132M but reverted to $-33M in Q1 2026, signaling no durable FCF recovery.

⚠ Total debt remains near $3B while equity has shrunk to $1,851M — debt-to-equity ratio now exceeds 1.5x and rising.

⚠ The $733M net loss in Q3 2025 implies a large impairment or write-down; monitor for further asset-quality deterioration.

⚠ Operating cash flow has swung sharply between quarters ($-98M to $+132M); sustained positive OCF is needed to service debt.

AI Insight: QDEL Ratio Trends

QuidelOrtho's profitability remains deeply impaired — a Q3 2025 impairment-driven collapse pushed TTM operating margin to -37% with no clear recovery path yet.

• Operating margin swung from a modest 4.7% in Q1 2025 to -100.7% in Q3 2025, then partially recovered to -5.1% in Q1 2026.

• D/E ratio rose steadily from 0.92 in Q2 2024 to 1.59 in Q4 2025, remaining at 1.58 in Q1 2026 — leverage is materially higher.

• ROIC improved sequentially from -58.0% in Q3 2025 to -2.7% in Q1 2026, though remains negative.

• Net profit margin has been negative in every quarter shown, ranging from -1.8% to -104.7%, signaling persistent bottom-line losses.

⚠ Q3 2025's -100.7% operating margin suggests a large non-cash charge; monitor whether write-downs recur in coming quarters.

⚠ D/E at 1.58 with consistently negative ROA (-6.5% in Q1 2026) raises debt-serviceability concerns if losses persist.

⚠ Sequential margin improvement from Q3 2025 trough to Q1 2026 warrants watching — a sustained positive operating margin has not yet been achieved.

Get alerted when QDEL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for QuidelOrtho Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of QDEL

BlackRock, Inc.
$171.7M10,449,127 sh
FMR LLC
$108.3M6,591,152 sh
Newtyn Management, LLC
$74.9M4,558,472 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$66.2M4,031,768 sh
Rubric Capital Management LP
$54.3M3,306,281 sh
Invesco Ltd.
$51.2M3,117,469 sh
VANGUARD CAPITAL MANAGEMENT LLC
$50.2M3,052,710 sh
DIMENSIONAL FUND ADVISORS LP
$50.1M3,048,768 sh
AMERICAN CENTURY COMPANIES INC
$46.9M2,856,132 sh
STATE STREET CORP
$45.8M2,786,621 sh

Fund	Value	Shares
BlackRock, Inc.	$171.7M	10,449,127
FMR LLC	$108.3M	6,591,152
Newtyn Management, LLC	$74.9M	4,558,472
VANGUARD PORTFOLIO MANAGEMENT LLC	$66.2M	4,031,768
Rubric Capital Management LP	$54.3M	3,306,281
Invesco Ltd.	$51.2M	3,117,469
VANGUARD CAPITAL MANAGEMENT LLC	$50.2M	3,052,710
DIMENSIONAL FUND ADVISORS LP	$50.1M	3,048,768
AMERICAN CENTURY COMPANIES INC	$46.9M	2,856,132
STATE STREET CORP	$45.8M	2,786,621

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put QDEL on your watchlist

Track score changes the day QuidelOrtho Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is QDEL a good stock to buy?

13F Pro's AI-powered analysis of QuidelOrtho Corp (QDEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QDEL are available on the QDEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own QDEL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QDEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of QuidelOrtho Corp's investment landscape.